Table 5 Options performance across the criteria attributes
Attribute | Metric | Lower level | Aflibercept + FOLFIRI | Cetuximab | Panitumumab | Higher level |
|---|---|---|---|---|---|---|
Overall survival | months | 6.2 | 13.5 | 10 | 10.4 | 14.9 |
HRQoL | utility (EQ-5D) | 0.75 | 0.78 | 0.78 | 0.78 | 0.9 |
Progression free survival | months | 1.9 | 6.9 | 4.1 | 4.4 | 7.6 |
Grade 4 AEs | % of patients | 10 | 21 | 5 | 7 | 0 |
ATC L4 | relative market entrance | 2nd | 1st | 1st | 2nd | 1st |
Phase 3 | # of new indications | 0 | 18 | 19 | 7 | 21 |
Marketing Authorisation | # of new indications | 0 | 3 | 1 | 0 | 3 |
Posology | duration & frequency | hours, every 2 weeks | hours, every 2 weeks | 1 hour, every week | ≤1 hour, every 2 weeks | ≤1 hour, every 2 weeks |
Medical costs impact | GBP (£) | 7,086 | 6,738 | 4,589 | 1,940 | 0 |